Alma

Alma Bio Therapeutics is a biopharmaceutical company focused on developing a new class of therapies for autoimmune and inflammatory diseases. The company's approach leverages the body's natural immune-regulating mechanisms, specifically targeting Heat Shock Protein 60 (HSP60) to induce the expansion of regulatory T cells (Tregs). Their lead program, ALM-201, is being developed for the treatment of Crohn's disease, aiming to restore immune tolerance rather than merely suppressing the immune system. By focusing on pro-tolerogenic pathways, Alma seeks to provide long-term remission for patients with chronic inflammatory conditions.